BioSpace News Archive

NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating central nervous system (CNS) injuries including stroke and traumatic brain injury, today announced the appointment of William Fricker, CPA, MBA, to Chief Financial Officer, effective immediately.

Recently, Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit.

Akebia Therapeutics ®, Inc. today announced the appointment of Nicholas Grund as Chief Commercial Officer.

Nevro Corp. today announced its preliminary, unaudited fourth-quarter and full-year 2023 revenue results.

NeuroSense Therapeutics Ltd. shares a review of important clinical achievements in 2023 and provides a road map for anticipated catalysts in 2024.

ValGenesis, Inc., the industry leader in digital validation, and GMP Pros, Inc., a leading engineering and technical solutions provider for the FDA regulated manufacturing industry, have partnered to introduce a suite of cutting-edge digital validation products from ValGenesis alongside GMP Pros’ extensive regulatory experience executing projects in life sciences for companies across the globe.

GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement for commercializing a radioimmunoconjugate product.

Illumina, Inc. today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2023 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 9:00am Pacific Time ( 12:00pm Eastern Time ).

OrthAlign Inc announces over $50MM in Global Revenue in its 2023 fiscal year, achieving record milestones in revenue, patient reach, and market expansion.

AcelRx Pharmaceuticals, Inc. today announced the rebranding of the Company, with a name change to Talphera, Inc. (“Talphera”).